It is worth noting that the exogenous administration of GILZ (TAT-GILZ) was shown to ameliorate the colitis symptoms in a mouse model of IBD, which provides a preclinical assessment of its efficacy in treating colitis [63]. The gene discussed is TSC22D3; the disease is inflammatory bowel disease.